Abstract
Background: A large number of chronic myeloid leukemia (CML) patients are treated with imatinib mesylate outside of clinical trials, which may not be representative of common clinical practice. The age of CML patients enrolled within controlled clinical studies is lower with respect to patients included in population-based registries. Patients and Methods: To describe the safety and tolerability of imatinib in very elderly CML patients in chronic phase, 211 chronic-phase CML patients aged >75 years were retrospectively analyzed using data collected from 31 institutions in Italy. Results: The median age at imatinib start was 78.6 years [interquartile range (IR) 76.3-81.4], median time from diagnosis to imatinib start was 1.2 months (IR 0.5-3.7). The starting dose of imatinib was 400 mg/day in 144 patients (68.2 %), >400 mg/day in 4 patients (2.0 %), and
Original language | English |
---|---|
Pages (from-to) | 629-637 |
Number of pages | 9 |
Journal | Drugs and Aging |
Volume | 30 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 2013 |
ASJC Scopus subject areas
- Pharmacology (medical)
- Geriatrics and Gerontology